Response to clozapine in a clinically identifiable subtype of schizophrenia - PubMed (original) (raw)
Observational Study
Response to clozapine in a clinically identifiable subtype of schizophrenia
Nancy J Butcher et al. Br J Psychiatry. 2015 Jun.
Abstract
Background: Genetic testing in psychiatry promises to improve patient care through advances in personalised medicine. However, there are few clinically relevant examples.
Aims: To determine whether patients with a well-established genetic subtype of schizophrenia show a different response profile to the antipsychotic clozapine than those with idiopathic schizophrenia.
Method: We retrospectively studied the long-term safety and efficacy of clozapine in 40 adults with schizophrenia, half with a 22q11.2 deletion (22q11.2DS group) and half matched for age and clinical severity but molecularly confirmed to have no pathogenic copy number variant (idiopathic group).
Results: Both groups showed similar clinical improvement and significant reductions in hospitalisations, achieved at a lower median dose for those in the 22q11.2DS group. Most common side-effects were similarly prevalent between the two groups, however, half of the 22q11.2DS group experienced at least one rare serious adverse event compared with none of the idiopathic group. Many were successfully retried on clozapine.
Conclusions: Individuals with 22q11.2DS-schizophrenia respond as well to clozapine treatment as those with other forms of schizophrenia, but may represent a disproportionate number of those with serious adverse events, primarily seizures. Lower doses and prophylactic (for example anticonvulsant) management strategies can help ameliorate side-effect risks. This first systematic evaluation of antipsychotic response in a genetic subtype of schizophrenia provides a proof-of-principle for personalised medicine and supports the utility of clinical genetic testing in schizophrenia.
© The Royal College of Psychiatrists 2015.
Conflict of interest statement
Declaration of interest None.
Figures
Fig. 1. Patients with 22q11.2 deletion syndrome (22q11.2DS) schizophrenia are maintained on a significantly lower therapeutic dose of clozapine than patients with idiopathic schizophrenia (P = 0.002)
The two 22q11.2DS-schizophrenia patients with doses ≤150 mg had been maintained in this range for at least 1 year; one was receiving adjunct antipsychotic flupentixol (4.5 mg) treatment. Of the three patients in the idiopathic group on a clozapine dose ≤150 mg, one was maintained on this dose for 4 years; the other two discontinued within 9 and 28 weeks, respectively (the latter on adjunct antipsychotic perphenazine (48 mg) treatment) and were not titrated above this low dose range.
Fig. 2. Clinical Global Impression – Improvement scale ratings for patients with 22q11.2 deletion syndrome (22q11.2DS) schizophrenia and idiopathic schizophrenia
Therapeutic response to clozapine of patients in the 22q11.2DS group is similar to those in the idiopathic group (P = 0.33). One of the two patients with no change corresponds to a patient in the idiopathic group with a clozapine dose ≤150 mg who discontinued within 28 weeks of treatment.
Similar articles
- A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome.
Tsurue A, Funahashi H, Tsurue K, Kawano M, Ishida Y, Hirano Y. Tsurue A, et al. Neuropsychopharmacol Rep. 2023 Jun;43(2):272-276. doi: 10.1002/npr2.12333. Epub 2023 Mar 16. Neuropsychopharmacol Rep. 2023. PMID: 36929244 Free PMC article. - Efficacy and safety of clozapine in treatment-resistant psychotic patients with DiGeorge syndrome (22q11.2 deletion syndrome): a case series.
Berardelli I, Cifrodelli M, Giuliani C, Antonelli G, Putotto C, Pulvirenti F, Pompili M. Berardelli I, et al. Int Clin Psychopharmacol. 2024 Jul 1;39(4):284-287. doi: 10.1097/YIC.0000000000000513. Epub 2023 Oct 13. Int Clin Psychopharmacol. 2024. PMID: 37824335 - Clozapine Use in 22q11.2 Deletion Syndrome: A Systematic Review of the Literature.
Colijn MA. Colijn MA. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):168-178. doi: 10.1097/JCP.0000000000001816. Epub 2024 Feb 10. J Clin Psychopharmacol. 2024. PMID: 38407281 - Clozapine use in children and adolescents.
Gogtay N, Rapoport J. Gogtay N, et al. Expert Opin Pharmacother. 2008 Feb;9(3):459-65. doi: 10.1517/14656566.9.3.459. Expert Opin Pharmacother. 2008. PMID: 18220495 Review. - Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
Van L, Boot E, Bassett AS. Van L, et al. Curr Opin Psychiatry. 2017 May;30(3):191-196. doi: 10.1097/YCO.0000000000000324. Curr Opin Psychiatry. 2017. PMID: 28230630 Review.
Cited by
- A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome.
Tsurue A, Funahashi H, Tsurue K, Kawano M, Ishida Y, Hirano Y. Tsurue A, et al. Neuropsychopharmacol Rep. 2023 Jun;43(2):272-276. doi: 10.1002/npr2.12333. Epub 2023 Mar 16. Neuropsychopharmacol Rep. 2023. PMID: 36929244 Free PMC article. - Genetic Mechanisms Behind Severe Psychotic Reactions to Levetiracetam.
Andrade DM. Andrade DM. Epilepsy Curr. 2022 Nov 29;23(1):29-31. doi: 10.1177/15357597221137409. eCollection 2023 Jan-Feb. Epilepsy Curr. 2022. PMID: 36923345 Free PMC article. No abstract available. - Increased Prevalence of Rare Copy Number Variants in Treatment-Resistant Psychosis.
Farrell M, Dietterich TE, Harner MK, Bruno LM, Filmyer DM, Shaughnessy RA, Lichtenstein ML, Britt AM, Biondi TF, Crowley JJ, Lázaro-Muñoz G, Forsingdal AE, Nielsen J, Didriksen M, Berg JS, Wen J, Szatkiewicz J, Mary Xavier R, Sullivan PF, Josiassen RC. Farrell M, et al. Schizophr Bull. 2023 Jul 4;49(4):881-892. doi: 10.1093/schbul/sbac175. Schizophr Bull. 2023. PMID: 36454006 Free PMC article. - Clinical management of psychosis in 22q11.2 deletion syndrome.
Iftimovici A, Krebs MO, Chaumette B. Iftimovici A, et al. J Psychiatry Neurosci. 2022 Nov 8;47(6):E391-E392. doi: 10.1503/jpn.220091. Print 2022 Nov-Dec. J Psychiatry Neurosci. 2022. PMID: 36347546 Free PMC article. No abstract available. - Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.
Pinzón-Espinosa J, van der Horst M, Zinkstok J, Austin J, Aalfs C, Batalla A, Sullivan P, Vorstman J, Luykx JJ. Pinzón-Espinosa J, et al. Transl Psychiatry. 2022 Oct 11;12(1):442. doi: 10.1038/s41398-022-02203-6. Transl Psychiatry. 2022. PMID: 36220808 Free PMC article. Review.
References
- Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011;25:933–69. - PubMed
- Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2011;11:1–14. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical